Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 18.16% is 37% above its 5-year average of 13.22%, near the high end of its 5-year range (9.20%–18.16%).
9.50% above its 12-month average of 16.59%.
Annual fiscal-year return on assets; no daily interpolation. Historical series through 2025-12-31.
RETURN ON ASSETS (ROA)
18.16%
RETURN ON ASSETS (ROA) AVG TTM
16.59%
RETURN ON ASSETS (ROA) AVG 3Y
14.73%
RETURN ON ASSETS (ROA) AVG 5Y
13.22%
RETURN ON ASSETS (ROA) AVG 10Y
15.36%
RETURN ON ASSETS (ROA) AVG 15Y
13.69%
RETURN ON ASSETS (ROA) AVG 20Y
13.04%
CURRENT VS TTM AVG
+9.50%
CURRENT VS 3Y AVG
+23.24%
CURRENT VS 5Y AVG
+37.42%
CURRENT VS 10Y AVG
+18.22%
CURRENT VS 15Y AVG
+32.63%
CURRENT VS 20Y AVG
+39.21%
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+253.31%
vs the sector median at left
United Therapeutics Corporation
Market Cap
$21.10B
Return on Assets (ROA)
18.16%
TTM Avg
16.59%
3Y Avg
14.73%
5Y Avg
13.22%
Market Cap
$19.23B
Return on Assets (ROA)
-1.17%
TTM Avg
-5.49%
3Y Avg
-1.68%
5Y Avg
-1.68%
Market Cap
$18.09B
Return on Assets (ROA)
3.54%
TTM Avg
3.64%
3Y Avg
3.29%
5Y Avg
2.38%
Market Cap
$24.30B
Return on Assets (ROA)
-8.40%
TTM Avg
-3.96%
3Y Avg
9.16%
5Y Avg
17.06%
Market Cap
$24.37B
Return on Assets (ROA)
13.86%
TTM Avg
12.54%
3Y Avg
14.20%
5Y Avg
14.86%
Market Cap
$24.62B
Return on Assets (ROA)
20.48%
TTM Avg
9.54%
3Y Avg
8.43%
5Y Avg
7.44%
Market Cap
$25.55B
Return on Assets (ROA)
5.41%
TTM Avg
4.41%
3Y Avg
4.42%
5Y Avg
6.18%
Market Cap
$16.40B
Return on Assets (ROA)
23.89%
TTM Avg
21.05%
3Y Avg
19.32%
5Y Avg
16.45%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $21.10B | 18.16% | 16.59% | 14.73% | 13.22% |
| STERIS plc (STE)vs › | $20.54B | 7.50% | 6.68% | 4.44% | 4.33% |
| Viatris Inc. (VTRS)vs › | $19.23B | -1.17% | -5.49% | -1.68% | -1.68% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.09B | 3.54% | 3.64% | 3.29% | 2.38% |
| BioNTech SE (BNTX)vs › | $24.30B | -8.40% | -3.96% | 9.16% | 17.06% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.37B | 13.86% | 12.54% | 14.20% | 14.86% |
| Incyte Corporation (INCY)vs › | $24.62B | 20.48% | 9.54% | 8.43% | 7.44% |
| Labcorp Holdings Inc. (LH)vs › | $25.55B | 5.41% | 4.41% | 4.42% | 6.18% |
| Medpace Holdings, Inc. (MEDP)vs › | $16.40B | 23.89% | 21.05% | 19.32% | 16.45% |
| Quest Diagnostics Incorporated (DGX)vs › | $25.94B | 6.27% | 5.75% | 6.24% | 8.30% |
ROA
18.2%
ROE
20.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 16.94% |
| 2024-12-31 | 16.23% |
| 2023-12-31 | 13.74% |
| 2022-12-31 | 12.03% |
| 2021-12-31 | 9.20% |
| 2020-12-31 | 11.15% |
| 2019-12-31 | -2.67% |
| 2018-12-31 | 17.32% |
| 2017-12-31 | 14.51% |
| 2016-12-31 | 30.69% |
| 2015-12-31 | 29.83% |
| 2014-12-31 | 18.05% |
| 2013-12-31 | 8.36% |
| 2012-12-31 | 18.72% |
| 2011-12-31 | 14.35% |
| 2010-12-31 | 7.40% |
| 2009-12-31 | 1.85% |
| 2008-12-31 | -4.91% |
| 2007-12-31 | 3.38% |
| 2006-12-31 | 15.46% |
| 2005-12-31 | 22.31% |
| 2004-12-31 | 7.46% |
| 2003-12-31 | -5.55% |
| 2002-12-31 | -12.81% |
| 2001-12-31 | -17.58% |
| 2000-12-31 | -30.17% |
| 1999-12-31 | -55.93% |
| 1998-12-31 | -68.45% |
